- Phare
- Validé par KD/KO
Anticorps Monoclonal anti-Cyclin B2
Cyclin B2 Monoclonal Antibody for WB, IHC, IF/ICC, IF-P, Indirect ELISA
Hôte / Isotype
Mouse / IgG2a
Réactivité testée
Humain, souris
Applications
WB, IHC, IF/ICC, IF-P, Indirect ELISA
Conjugaison
Non conjugué
CloneNo.
2G8B7
N° de cat : 67726-1-PBS
Synonymes
Galerie de données de validation
Informations sur le produit
67726-1-PBS cible Cyclin B2 dans les applications de WB, IHC, IF/ICC, IF-P, Indirect ELISA et montre une réactivité avec des échantillons Humain, souris
| Réactivité | Humain, souris |
| Hôte / Isotype | Mouse / IgG2a |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | Cyclin B2 Protéine recombinante Ag16329 |
| Nom complet | cyclin B2 |
| Masse moléculaire calculée | 398 aa, 45 kDa |
| Poids moléculaire observé | 45 kDa |
| Numéro d’acquisition GenBank | BC105086 |
| Symbole du gène | Cyclin B2 |
| Identification du gène (NCBI) | 9133 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS only |
| Conditions de stockage | Store at -80°C. 20ul contiennent 0,1% de BSA. |
Informations générales
Cyclin B2 (CCNB2) is a member of cyclin family proteins, which regulate the activities of cyclin dependent kinases (CDKs) and different cyclins function spatially and temporally in specific phases of the cell cycle. Cyclin B2 serves a key role in progression of G2/M transition. Cyclin B2 has been found to be up-regulated in a variety of human cancers, such as adrenocortical carcinoma, breast carcinoma, colorectal adenocarcinoma, pituitary adenoma and gastric cancer. The aberrant expression of Cyclin B2 deregulates spindle checkpoints in the cell cycle and results in chromosomal instability (CIN), one of the signature phenotypes of most cancers. Moreover, serum circulating Cyclin B2 mRNA expression has been found increased in cancer patients and associated with cancer stage and metastasis status.













